Epidemiology, risk factors and management of cardiovascular diseases in IBD

[1]  Peter Seizer,et al.  Platelets in Inflammation and Atherogenesis , 2015, Front. Immunol..

[2]  S. Kapadia,et al.  Conventional risk factors and cardiovascular outcomes of patients with inflammatory bowel disease with confirmed coronary artery disease. , 2014, Inflammatory bowel diseases.

[3]  E. Serné,et al.  Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis , 2013, Annals of the rheumatic diseases.

[4]  A. Burroughs,et al.  Results of systematic review and meta-analysis , 2015 .

[5]  M. Okano,et al.  Cohort Study , 2020, Definitions.

[6]  R. Erichsen,et al.  Inflammatory Bowel Disease Is Associated With an Increased Risk of Hospitalization for Heart Failure: A Danish Nationwide Cohort Study , 2014, Circulation. Heart failure.

[7]  W. Zidek,et al.  Harmful Effects of the Azathioprine Metabolite 6-Mercaptopurine in Vascular Cells: Induction of Mineralization , 2014, PloS one.

[8]  S. Laurent,et al.  Increased arterial stiffness in inflammatory bowel diseases is dependent upon inflammation and reduced by immunomodulatory drugs. , 2014, Atherosclerosis.

[9]  O. Giouleme,et al.  Carotid Intima-Media Thickness in Patients With Inflammatory Bowel Disease , 2014, Angiology.

[10]  Siddharth Singh,et al.  Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  A. Griffiths,et al.  Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. , 2014, Gastroenterology.

[12]  Hisashi Adachi,et al.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.

[13]  Siddharth Singh,et al.  Cardiovascular risk in inflammatory bowel disease: it's a heartache! , 2013, Gastroenterology.

[14]  A. Di Leo,et al.  Endothelial function and cardiovascular risk in active inflammatory bowel diseases. , 2013, Journal of Crohn's & colitis.

[15]  Amir Lerman,et al.  Endothelial dysfunction over the course of coronary artery disease. , 2013, European Heart Journal.

[16]  S. Gabriel,et al.  Rheumatoid arthritis and cardiovascular disease. , 2013, American heart journal.

[17]  I. McInnes,et al.  Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm , 2013, Nature Reviews Rheumatology.

[18]  P. Gibson,et al.  Venous and arterial disease in inflammatory bowel disease , 2013, Journal of gastroenterology and hepatology.

[19]  H. Yuhara,et al.  Meta‐analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease , 2013, Alimentary pharmacology & therapeutics.

[20]  I. Koutroubakis,et al.  Risk of Venous Thromboembolism in Patients with Inflammatory Bowel Disease , 2013, Seminars in Thrombosis & Hemostasis.

[21]  R. Erichsen,et al.  Disease Activity in Inflammatory Bowel Disease Is Associated with Increased Risk of Myocardial Infarction, Stroke and Cardiovascular Death – A Danish Nationwide Cohort Study , 2013, PloS one.

[22]  Cheuk-Man Yu,et al.  Infliximab is Associated with Improvement in Arterial Stiffness in Patients with Early Rheumatoid Arthritis — A Randomized Trial , 2012, The Journal of Rheumatology.

[23]  M. Rachchh,et al.  Evaluation of anti-inflammatory effect of anti-platelet agent-clopidogrel in experimentally induced inflammatory bowel disease , 2012, Indian Journal of Pharmacology.

[24]  G. Di Nardo,et al.  Premature subclinical atherosclerosis in pediatric inflammatory bowel disease. , 2012, The Journal of pediatrics.

[25]  J. Wohlfahrt,et al.  Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study , 2012, Gut.

[26]  S. Laurent,et al.  Arterial stiffness is increased in patients with inflammatory bowel disease , 2012, Journal of hypertension.

[27]  B. Korelitz,et al.  The effect of antiplatelet therapy in patients with inflammatory bowel disease. , 2012, Journal of clinical gastroenterology.

[28]  Seth D. Crockett,et al.  Statins are associated with reduced use of steroids in inflammatory bowel disease: A retrospective cohort study* , 2012, Inflammatory bowel diseases.

[29]  Sumant Inamdar,et al.  Tu1285 Increased Risk of Coronary Artery Disease Among Patients With Inflammatory Bowel Disease , 2012 .

[30]  M. Barvaliya,et al.  Evaluation of the concomitant use of methotrexate and curcumin on Freund's complete adjuvant-induced arthritis and hematological indices in rats , 2012, Indian Journal of Pharmacology.

[31]  M. Turiel,et al.  Validated methods for assessment of subclinical atherosclerosis in rheumatology , 2012, Nature Reviews Rheumatology.

[32]  J. Aviña-Zubieta,et al.  Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies , 2012, Annals of the rheumatic diseases.

[33]  A. Ananthakrishnan,et al.  Aspirin, Nonsteroidal Anti-inflammatory Drug Use, and Risk for Crohn Disease and Ulcerative Colitis , 2012, Annals of Internal Medicine.

[34]  F. Asselbergs,et al.  Gender gap in acute coronary heart disease: Myth or reality? , 2012, World journal of cardiology.

[35]  K. Bornfeldt,et al.  S100A8 and S100A9 in cardiovascular biology and disease. , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[36]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[37]  D. Greenwood,et al.  Meta-analysis of Observational Studies , 2012 .

[38]  K. Higuchi,et al.  Simvastatin Attenuates Intestinal Fibrosis Independent of the Anti-Inflammatory Effect by Promoting Fibroblast/Myofibroblast Apoptosis in the Regeneration/Healing Process from TNBS-Induced Colitis , 2012, Digestive Diseases and Sciences.

[39]  L. Peyrin-Biroulet,et al.  Meta‐analysis: hyperhomocysteinaemia in inflammatory bowel diseases , 2011, Alimentary pharmacology & therapeutics.

[40]  C. Brensinger,et al.  No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[41]  E. Riboli,et al.  Aspirin in the aetiology of Crohn’s disease and ulcerative colitis: a European prospective cohort study , 2011, Alimentary pharmacology & therapeutics.

[42]  L. Skov,et al.  Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study , 2011, Journal of Internal Medicine.

[43]  G. Tonini,et al.  Association between NOD2/CARD15 polymorphisms and coronary artery disease: a case-control study. , 2011, Human immunology.

[44]  W. Dixon,et al.  The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. , 2011, Rheumatology.

[45]  S. Gabriel,et al.  Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE , 2011, Nature Reviews Rheumatology.

[46]  S. Gruber,et al.  Risk of colorectal cancer in self‐reported inflammatory bowel disease and modification of risk by statin and NSAID use , 2011, Cancer.

[47]  L. Tamariz,et al.  Inflammatory Bowel Disease Is Associated With an Increased Incidence of Cardiovascular Events , 2011, The American Journal of Gastroenterology.

[48]  P. Higgins,et al.  The Prognostic Power of the NOD2 Genotype for Complicated Crohn's Disease: A Meta-Analysis , 2011, The American Journal of Gastroenterology.

[49]  M. Färkkilä,et al.  Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. , 2011, Journal of Crohn's & colitis.

[50]  E. Lonn,et al.  Microvascular Function Predicts Cardiovascular Events in Primary Prevention: Long-Term Results From the Firefighters and Their Endothelium (FATE) Study , 2011, Circulation.

[51]  P. Higgins,et al.  The Prognostic Power of the NOD 2 Genotype for Complicated Crohn ’ s Disease : A Meta-Analysis , 2011 .

[52]  K. Mullen,et al.  Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease. , 2010, Journal of clinical lipidology.

[53]  M. Bots,et al.  High Myeloid-Related Protein: 8/14 Levels Are Related to an Increased Risk of Cardiovascular Events After Carotid Endarterectomy , 2010, Stroke.

[54]  Edeltraut Garbe,et al.  Risk of ischemic stroke in patients with Crohn's disease: A population‐based nested case‐control study† , 2010, Inflammatory bowel diseases.

[55]  黄亚明（整理）,et al.  Canadian Association of Gastroenterology , 2010 .

[56]  Carl J Pepine,et al.  Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study. , 2010, Journal of the American College of Cardiology.

[57]  Samuel Z Goldhaber,et al.  Venous thromboembolism and atherothrombosis: an integrated approach. , 2010, Circulation.

[58]  W. Ageno,et al.  Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta‐analysis , 2010, Journal of thrombosis and haemostasis : JTH.

[59]  S. Pedersen,et al.  Plasma calprotectin predicts mortality in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention. , 2010, Journal of interventional cardiology.

[60]  C. Vlachopoulos,et al.  Prediction of Cardiovascular Events and All-Cause Mortality With Arterial Stiffness , 2011 .

[61]  J. West,et al.  Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study , 2010, The Lancet.

[62]  Z. Szekanecz,et al.  Vascular effects of biologic agents in RA and spondyloarthropathies , 2009, Nature Reviews Rheumatology.

[63]  C. Noel Bairey Merz,et al.  Women and ischemic heart disease: evolving knowledge. , 2009, Journal of the American College of Cardiology.

[64]  P. Libby,et al.  Myeloid-Related Protein-8/14 Is Critical for the Biological Response to Vascular Injury , 2009, Circulation.

[65]  James G Wright,et al.  A Population-Based Nested Case-Control Study of the Costs of Hip and Knee Replacement Surgery , 2009, Medical care.

[66]  N. Fahmy,et al.  Inflammatory bowel disease and coronary artery disease , 2009, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.

[67]  C. Ha,et al.  Risk of Arterial Thrombotic Events in Inflammatory Bowel Disease , 2009, The American Journal of Gastroenterology.

[68]  O. Grip,et al.  Atorvastatin Reduces Plasma Levels of Chemokine (CXCL10) in Patients with Crohn's Disease , 2009, PloS one.

[69]  Joe McCarthy,et al.  An integrated approach , 2001 .

[70]  N. Malliaraki,et al.  Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease , 2009, European journal of gastroenterology & hepatology.

[71]  E. Manzato,et al.  Plasma lipids and inflammation in active inflammatory bowel diseases , 2009, Alimentary pharmacology & therapeutics.

[72]  I. Roifman,et al.  Evidence of endothelial dysfunction in patients with inflammatory bowel disease. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[73]  In Sung Song,et al.  Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis‐associated colon cancer in mice , 2008, International journal of cancer.

[74]  F. Schmidt.  Meta-Analysis , 2008 .

[75]  C. Bernstein,et al.  The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[76]  E. Horváth-Puhó,et al.  Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study , 2007, The Lancet.

[77]  S. Schreiber,et al.  Role of NOD2/CARD15 in coronary heart disease , 2007, BMC Genetics.

[78]  R. Sandler,et al.  Inflammatory Bowel Disease Is Not a Risk Factor for Cardiovascular Disease Mortality: Results from a Systematic Review and Meta-Analysis , 2007, The American Journal of Gastroenterology.

[79]  Matthias W. Lorenz,et al.  Prediction of Clinical Cardiovascular Events With Carotid Intima-Media Thickness: A Systematic Review and Meta-Analysis , 2007, Circulation.

[80]  이종열.  Simvastatin inhibits NF-κB signaling in intestinal epithelial cells and ameliorates acute murine colitis , 2007 .

[81]  Nancy R Cook,et al.  The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for Women , 2006, Annals of Internal Medicine.

[82]  J. Galmiche,et al.  Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. , 2006, Metabolism: clinical and experimental.

[83]  Y. Naito,et al.  Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice. , 2006, International journal of molecular medicine.

[84]  E. Małecka-Panas,et al.  Plasma total homocysteine in the active stage of ulcerative colitis , 2006, Journal of gastroenterology and hepatology.

[85]  Simon Smale,et al.  Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[86]  A. Gasbarrini,et al.  Increased carotid intima–media thickness in patients with inflammatory bowel disease , 2005, Alimentary pharmacology & therapeutics.

[87]  S. Gabriel,et al.  Cardiovascular death in rheumatoid arthritis: a population-based study. , 2005, Arthritis and rheumatism.

[88]  D. Rader,et al.  The effects of statin therapy on plasma markers of inflammation in patients without vascular disease , 2005, Clinical cardiology.

[89]  François Mach,et al.  Inflammation and Atherosclerosis , 2004, Herz.

[90]  T. MacDonald,et al.  Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease , 2004, Annals of Internal Medicine.

[91]  M. Pines,et al.  Prevention of Fibrosis in Experimental Colitis by Captopril: the Role of tgf-β1 , 2004, Inflammatory bowel diseases.

[92]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[93]  S. Danese,et al.  Platelets in Inflammatory Bowel Disease: Clinical, Pathogenic, and Therapeutic Implications , 2004, American Journal of Gastroenterology.

[94]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[95]  E. Kouroumalis,et al.  Anti-cardiolipin and Anti-β2-glycoprotein I Antibodies in Patients with Inflammatory Bowel Disease , 1998, Digestive Diseases and Sciences.

[96]  E. Chung,et al.  Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial , 2003, Circulation.

[97]  C. A. de la Motte,et al.  Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. , 2003, Gastroenterology.

[98]  T. Joh,et al.  The 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitor Pravastatin Reduces Disease Activity and Inflammation in Dextran-Sulfate Induced Colitis , 2003, Journal of Pharmacology and Experimental Therapeutics.

[99]  L. van Nueten,et al.  Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double‐blind studies , 2002, Alimentary pharmacology & therapeutics.

[100]  N. Malliaraki,et al.  Increased levels of lipoprotein (a) in Crohn's disease: a relation to thrombosis? , 2001, European journal of gastroenterology & hepatology.

[101]  P. Rutgeerts,et al.  Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo‐controlled, double‐blind, multi‐centre clinical trial in active Crohn’s disease , 2001, Alimentary pharmacology & therapeutics.

[102]  M. Macey,et al.  Inhibition of platelet activation by 5‐aminosalicylic acid in inflammatory bowel disease , 2000, Alimentary pharmacology & therapeutics.

[103]  Aldons J. Lusis,et al.  Atherosclerosis : Vascular biology , 2000 .

[104]  G. Hankey,et al.  Homocysteine and vascular disease , 1999, The Lancet.

[105]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[106]  G. Omenn,et al.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. , 1995, JAMA.

[107]  D. Rampton,et al.  Platelets circulate in an activated state in inflammatory bowel disease. , 1994, Gastroenterology.

[108]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[109]  M. Webberley,et al.  Thromboembolism in inflammatory bowel disease: role of platelets. , 1993, Gut.

[110]  R. Jaszewski,et al.  Increased colonic mucosal angiotensin I and II concentrations in Crohn's colitis. , 1990, Gastroenterology.